Medical Marijuana Research: The Cannabis Consortium Review of the Literature

Sharon Anavi-Goffer, Michael Bloch, Cathy Budman, Barbara Coffey, Keith Coffman, Joohi Jimenez-Shahed, Irene Malaty, Kirsten Muller-Vahl, Paul Sandor, Diana Shineman, John Walkup, Abraham Weizman, International Advisory Consortium on Medical cannabis/related drugs for Tourette and Tic Disorders

Research output: Book/ReportOther Report

Abstract

The Tourette Association of America (TAA) understands and supports the need to improve the treatment of Tourette Syndrome (TS), Tic Disorders, and co-occurring conditions. The TAA has a track record of funding the development, evaluation and dissemination of effective treatments including pharmacological, behavioral and alternative therapies that reduce the burden of TS and Tic Disorders on our community. Based on currently available evidence, we provide here our current summary of the existing literature on the use of medical marijuana (cannabis) and cannabis-based medications for TS:

A reduction in tics with medical marijuana and cannabis-based medicines has been reported in small studies, patient reports and anecdotal case reports. The neurobiological pathways targeted by medical marijuana and related therapies are deserving of more research and larger scale studies.
There is the potential for adverse effects from medical marijuana and related plant-derived extracts that raise concern for treatment, especially in children and adolescents.
The TAA supports removing regulatory barriers to allow for large-scale research studies of medical marijuana. There is currently insufficient scientific evidence to reach a definitive conclusion on the efficacy and safety of medical marijuana, cannabis-based medications, or related plant-derived extracts for the treatment of TS and other Tic Disorders.
Original languageEnglish
PublisherTourette Association of America
Number of pages10
Publication statusPublished - 12 Sep 2019

Fingerprint

Medical Marijuana
Cannabis
Biomedical Research
Tourette Syndrome
Tic Disorders
Plant Extracts
Therapeutics
Tics
Complementary Therapies
Research
Pharmacology

Keywords

  • 888-4-TOURET

Cite this

Anavi-Goffer, S., Bloch, M., Budman, C., Coffey, B., Coffman, K., Jimenez-Shahed, J., ... International Advisory Consortium on Medical cannabis/related drugs for Tourette and Tic Disorders (2019). Medical Marijuana Research: The Cannabis Consortium Review of the Literature. Tourette Association of America.

Medical Marijuana Research : The Cannabis Consortium Review of the Literature. / Anavi-Goffer, Sharon; Bloch, Michael; Budman, Cathy; Coffey, Barbara; Coffman, Keith; Jimenez-Shahed, Joohi; Malaty, Irene; Muller-Vahl, Kirsten; Sandor, Paul; Shineman, Diana; Walkup, John; Weizman, Abraham; International Advisory Consortium on Medical cannabis/related drugs for Tourette and Tic Disorders.

Tourette Association of America, 2019. 10 p.

Research output: Book/ReportOther Report

Anavi-Goffer, S, Bloch, M, Budman, C, Coffey, B, Coffman, K, Jimenez-Shahed, J, Malaty, I, Muller-Vahl, K, Sandor, P, Shineman, D, Walkup, J, Weizman, A & International Advisory Consortium on Medical cannabis/related drugs for Tourette and Tic Disorders 2019, Medical Marijuana Research: The Cannabis Consortium Review of the Literature. Tourette Association of America.
Anavi-Goffer S, Bloch M, Budman C, Coffey B, Coffman K, Jimenez-Shahed J et al. Medical Marijuana Research: The Cannabis Consortium Review of the Literature. Tourette Association of America, 2019. 10 p.
Anavi-Goffer, Sharon ; Bloch, Michael ; Budman, Cathy ; Coffey, Barbara ; Coffman, Keith ; Jimenez-Shahed, Joohi ; Malaty, Irene ; Muller-Vahl, Kirsten ; Sandor, Paul ; Shineman, Diana ; Walkup, John ; Weizman, Abraham ; International Advisory Consortium on Medical cannabis/related drugs for Tourette and Tic Disorders. / Medical Marijuana Research : The Cannabis Consortium Review of the Literature. Tourette Association of America, 2019. 10 p.
@book{03dcdf3723d24b2f989b6b19fa84d5b9,
title = "Medical Marijuana Research: The Cannabis Consortium Review of the Literature",
abstract = "The Tourette Association of America (TAA) understands and supports the need to improve the treatment of Tourette Syndrome (TS), Tic Disorders, and co-occurring conditions. The TAA has a track record of funding the development, evaluation and dissemination of effective treatments including pharmacological, behavioral and alternative therapies that reduce the burden of TS and Tic Disorders on our community. Based on currently available evidence, we provide here our current summary of the existing literature on the use of medical marijuana (cannabis) and cannabis-based medications for TS:A reduction in tics with medical marijuana and cannabis-based medicines has been reported in small studies, patient reports and anecdotal case reports. The neurobiological pathways targeted by medical marijuana and related therapies are deserving of more research and larger scale studies.There is the potential for adverse effects from medical marijuana and related plant-derived extracts that raise concern for treatment, especially in children and adolescents.The TAA supports removing regulatory barriers to allow for large-scale research studies of medical marijuana. There is currently insufficient scientific evidence to reach a definitive conclusion on the efficacy and safety of medical marijuana, cannabis-based medications, or related plant-derived extracts for the treatment of TS and other Tic Disorders.",
keywords = "888-4-TOURET",
author = "Sharon Anavi-Goffer and Michael Bloch and Cathy Budman and Barbara Coffey and Keith Coffman and Joohi Jimenez-Shahed and Irene Malaty and Kirsten Muller-Vahl and Paul Sandor and Diana Shineman and John Walkup and Abraham Weizman and {International Advisory Consortium on Medical cannabis/related drugs for Tourette and Tic Disorders}",
note = "TAA partners with many corporations including pharmaceutical companies. Abide Pharmaceuticals, mentioned in this report, is developing a synthetic monoacylglycerol lipase (MAGL) inhibitor for Tourette Syndrome, is a corporate sponsor of TAA. The TAA does not endorse any medicines or products.",
year = "2019",
month = "9",
day = "12",
language = "English",
publisher = "Tourette Association of America",

}

TY - BOOK

T1 - Medical Marijuana Research

T2 - The Cannabis Consortium Review of the Literature

AU - Anavi-Goffer, Sharon

AU - Bloch, Michael

AU - Budman, Cathy

AU - Coffey, Barbara

AU - Coffman, Keith

AU - Jimenez-Shahed, Joohi

AU - Malaty, Irene

AU - Muller-Vahl, Kirsten

AU - Sandor, Paul

AU - Shineman, Diana

AU - Walkup, John

AU - Weizman, Abraham

AU - International Advisory Consortium on Medical cannabis/related drugs for Tourette and Tic Disorders

N1 - TAA partners with many corporations including pharmaceutical companies. Abide Pharmaceuticals, mentioned in this report, is developing a synthetic monoacylglycerol lipase (MAGL) inhibitor for Tourette Syndrome, is a corporate sponsor of TAA. The TAA does not endorse any medicines or products.

PY - 2019/9/12

Y1 - 2019/9/12

N2 - The Tourette Association of America (TAA) understands and supports the need to improve the treatment of Tourette Syndrome (TS), Tic Disorders, and co-occurring conditions. The TAA has a track record of funding the development, evaluation and dissemination of effective treatments including pharmacological, behavioral and alternative therapies that reduce the burden of TS and Tic Disorders on our community. Based on currently available evidence, we provide here our current summary of the existing literature on the use of medical marijuana (cannabis) and cannabis-based medications for TS:A reduction in tics with medical marijuana and cannabis-based medicines has been reported in small studies, patient reports and anecdotal case reports. The neurobiological pathways targeted by medical marijuana and related therapies are deserving of more research and larger scale studies.There is the potential for adverse effects from medical marijuana and related plant-derived extracts that raise concern for treatment, especially in children and adolescents.The TAA supports removing regulatory barriers to allow for large-scale research studies of medical marijuana. There is currently insufficient scientific evidence to reach a definitive conclusion on the efficacy and safety of medical marijuana, cannabis-based medications, or related plant-derived extracts for the treatment of TS and other Tic Disorders.

AB - The Tourette Association of America (TAA) understands and supports the need to improve the treatment of Tourette Syndrome (TS), Tic Disorders, and co-occurring conditions. The TAA has a track record of funding the development, evaluation and dissemination of effective treatments including pharmacological, behavioral and alternative therapies that reduce the burden of TS and Tic Disorders on our community. Based on currently available evidence, we provide here our current summary of the existing literature on the use of medical marijuana (cannabis) and cannabis-based medications for TS:A reduction in tics with medical marijuana and cannabis-based medicines has been reported in small studies, patient reports and anecdotal case reports. The neurobiological pathways targeted by medical marijuana and related therapies are deserving of more research and larger scale studies.There is the potential for adverse effects from medical marijuana and related plant-derived extracts that raise concern for treatment, especially in children and adolescents.The TAA supports removing regulatory barriers to allow for large-scale research studies of medical marijuana. There is currently insufficient scientific evidence to reach a definitive conclusion on the efficacy and safety of medical marijuana, cannabis-based medications, or related plant-derived extracts for the treatment of TS and other Tic Disorders.

KW - 888-4-TOURET

M3 - Other Report

BT - Medical Marijuana Research

PB - Tourette Association of America

ER -